OKYO Pharma Company Leadership
| OKYO Stock | USD 1.04 0.01 0.95% |
OKYO Pharma employs about 8 people. The company is managed by 5 executives with a total tenure of roughly 19 years, averaging almost 3.0 years of service per executive, having 1.6 employees per reported executive. Analysis of OKYO Pharma's management performance can provide insight into the firm performance.
OKYO |
OKYO Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (2.9187) % which means that it has lost $2.9187 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (29.6851) %, meaning that it created substantial loss on money invested by shareholders. OKYO Pharma's management efficiency ratios could be used to measure how well OKYO Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Equity is likely to grow to 0, while Return On Tangible Assets are likely to drop (0.01). As of the 27th of November 2024, Intangible Assets is likely to grow to about 8.9 M, while Total Assets are likely to drop about 1.5 M.As of the 27th of November 2024, Common Stock Shares Outstanding is likely to drop to about 27.9 M. In addition to that, Net Loss is likely to drop to about (4.8 M)
OKYO Pharma Workforce Comparison
OKYO Pharma Ltd is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 384. OKYO Pharma holds roughly 8.0 in number of employees claiming about 2.08% of equities under Health Care industry.
OKYO Pharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific OKYO Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on OKYO Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, OKYO Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Denoyer Bernard over six months ago Disposition of 1000000 shares by Denoyer Bernard of OKYO Pharma at 0.1045 subject to Rule 16b-3 | ||
Cerrone Gabriele M over a year ago Acquisition or disposition of OKYO Pharma securities by Cerrone Gabriele M | ||
Brancaccio John P over a year ago Purchase by Brancaccio John P of 16670 shares of OKYO Pharma |
OKYO Pharma Notable Stakeholders
An OKYO Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as OKYO Pharma often face trade-offs trying to please all of them. OKYO Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting OKYO Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michael Beck | Founder | Profile | |
| Keeren Shah | Chief Officer | Profile | |
| PharmD Clementi | Chief Officer | Profile | |
| Rajkumar Patil | Chief Officer | Profile | |
| Gary Jacob | CEO Director | Profile |
About OKYO Pharma Management Performance
The success or failure of an entity such as OKYO Pharma often depends on how effective the management is. OKYO Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of OKYO management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the OKYO management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.01) | (0.01) | |
| Return On Assets | (0.01) | (0.01) |
OKYO Pharma Workforce Analysis
Traditionally, organizations such as OKYO Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare OKYO Pharma within its industry.OKYO Pharma Manpower Efficiency
Return on OKYO Pharma Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 2.1M | |
| Net Loss Per Executive | 3.4M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OKYO Pharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OKYO Pharma. If investors know OKYO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OKYO Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.57) | Return On Assets (2.92) | Return On Equity (29.69) |
The market value of OKYO Pharma is measured differently than its book value, which is the value of OKYO that is recorded on the company's balance sheet. Investors also form their own opinion of OKYO Pharma's value that differs from its market value or its book value, called intrinsic value, which is OKYO Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OKYO Pharma's market value can be influenced by many factors that don't directly affect OKYO Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OKYO Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if OKYO Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OKYO Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.